FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 山東威高集團醫用高分子製品股份有限公司 呈交日期： 2025年11月14日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 01066 | 說明 | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | | 庫存股份變動 | | | | 事件 | | 已發行股份（不包括庫存股份）數 目 ...

Summary of Key Points Core Viewpoint - A total of 30 companies conducted share buybacks on November 13, 2025, with China Feihe (06186) leading in both the number of shares repurchased and the total amount spent on buybacks, amounting to 20 million shares and 87.858 million yuan respectively [1][2]. Group 1: Buyback Details - China Feihe (06186) repurchased 20 million shares for 87.858 million yuan, with a year-to-date total of 117 million shares, representing 1.294% of its total share capital [2]. - COSCO Shipping Holdings (01919) repurchased 3 million shares for 42.9502 million yuan, with a year-to-date total of 25.188 million shares, accounting for 0.875% of its total share capital [2]. - China International Marine Containers (02039) repurchased 2.8054 million shares for 20.01 million yuan, with a year-to-date total of 3.66303 million shares, representing 1.190% of its total share capital [2]. Group 2: Other Notable Buybacks - Sinopec Limited (00386) repurchased 3.468 million shares for 15.3039 million yuan, with a year-to-date total of 139 million shares, accounting for 0.110% of its total share capital [2]. - Yip's Chemical Holdings (06826) repurchased 39,500 shares for 1.1077 million yuan, with a year-to-date total of 580,100 shares, representing 1.482% of its total share capital [3]. - Kangji Medical Holdings (01681) repurchased 20 million shares for 300,000 yuan, with a year-to-date total of 9.898 million shares, accounting for 11.627% of its total share capital [3].

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 山東威高集團醫用高分子製品股份有限公司 呈交日期： 2025年11月13日 根據《主板上市規則》第13.25C條 / 《GEM上市規則》第17.27C條，我們在此確認，據我們所知所信，第一章節所述的每項股份發行或庫存股份出售或轉讓已獲發行人董事會正式授權批准，並遵 照所有適用上市規則、法律及其他監管規定進行，並在適用的情況下： (註7) (i) 上市發行人已收取其在是次股份發行或庫存股份出售或轉讓應得的全部款項； (viii) 有關債券、借貸股份、票據或公司債券的信託契約/平邊契據經已製備及簽署，有關詳情已送呈公司註冊處處長存檔（如法律如此規定）。 第一章節註釋： 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | ...

Summary of Key Points Core Viewpoint - A total of 30 companies conducted share buybacks on November 12, 2025, with China COSCO Shipping Holdings (01919) leading in terms of buyback amount and quantity. Group 1: Buyback Details - China COSCO Shipping Holdings (01919) repurchased 3 million shares for a total of 43.1382 million yuan, representing 0.770% of its total share capital [1][2] - Sinopec Limited (00386) repurchased 3.708 million shares for 16.5210 million yuan, accounting for 0.110% of its total share capital [2] - China International Marine Containers (02039) repurchased 2 million shares for 14.1189 million yuan, which is 1.090% of its total share capital [2] Group 2: Other Notable Buybacks - China Feihe Limited (06186) repurchased 2 million shares for 8.8511 million yuan, representing 1.074% of its total share capital [2] - AAC Technologies Holdings (02018) repurchased 221,500 shares for 8.8302 million yuan, which is 0.186% of its total share capital [2] - Linklogis Inc. (09959) repurchased 1,208,000 shares for 3.7894 million yuan, accounting for 4.685% of its total share capital [2] Group 3: Additional Companies - Mobi Development (00947) repurchased 50,000 shares for 8.0500 million yuan, which is 0.222% of its total share capital [3] - Tianfu (06868) repurchased 10,000 shares for 30,000 yuan, representing 0.051% of its total share capital [3] - Hylink Digital Solutions (01586) repurchased 80,000 shares for 22,100 yuan, accounting for 4.305% of its total share capital [3]

Core Viewpoint - Weigao Co., Ltd. announced a share buyback plan, indicating confidence in its stock value and future prospects [1] Group 1 - The company will repurchase 500,000 shares at a total cost of HKD 2.7784 million [1] - The buyback price per share ranges from HKD 5.52 to HKD 5.60 [1] - The buyback is scheduled for November 12, 2025 [1]

Group 1 - The company, Weigao Group (01066.HK), announced a share buyback plan on November 12, 2025, involving an expenditure of HKD 2.778 million to repurchase 500,000 shares [1] - The buyback price is set between HKD 5.52 and HKD 5.60 per share [1]

Core Viewpoint - Weigao Co., Ltd. announced a share buyback plan, indicating confidence in its stock value and future prospects [1] Summary by Categories Company Actions - Weigao Co., Ltd. plans to repurchase 500,000 shares at a total cost of HKD 2.7784 million [1] - The buyback price per share ranges from HKD 5.52 to HKD 5.60 [1] Financial Implications - The total expenditure for the share buyback reflects the company's strategy to enhance shareholder value [1]

翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 山東威高集團醫用高分子製品股份有限公司 呈交日期： 2025年11月12日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 01066 | 說明 | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | | 庫存股份變動 | | | | | 事件 | 已發行股份（不包括庫存股份）數 目 | | 佔 ...

Core Viewpoint - Zhongtai International has set the target price for Weigao Co., Ltd. (01066) at HKD 5.94, maintaining a "Buy" rating while adjusting revenue forecasts for 2025-2027 down by 5.2%, 5.9%, and 6.0% respectively, and net profit forecasts down by 6.4%, 5.4%, and 5.8%, although both revenue and profit are still expected to achieve positive growth [1] Group 1 - The company achieved positive revenue growth in the first three quarters of 2025, with a 2.6% year-on-year increase in Q3 revenue to RMB 3.26 billion, leading to a total revenue increase of 0.9% to approximately RMB 9.81 billion for the first three quarters, slightly below expectations [2] - The medical device and pharmaceutical packaging segments were impacted by the centralized procurement of low-value consumables and syringe procurement, but sales of orthopedic products are expected to improve in the second half of the year, while sales of interventional and blood management products continue to grow rapidly [2] Group 2 - The pharmaceutical packaging business experienced a slight decline in revenue due to centralized procurement of syringes, with a year-on-year decrease of 0.1% in the first half and only low single-digit growth in Q3; revenue forecasts for the pharmaceutical packaging business for 2025-2027 have been adjusted down by 8.9%, 13.5%, and 13.4% respectively [3] - The impact of centralized procurement on the medical device segment has largely been reflected, with the expectation that sales revenue will gradually recover starting in 2026 as the nationwide implementation of low-value consumables procurement has been completed [4] Group 3 - The orthopedic business is expected to recover in the second half of the year as the company shifts its sales model from direct sales to distribution in 2025; after a 1.6% year-on-year decline in sales revenue in the first half due to the adjustment period with distributors, Q3 sales revenue for this segment increased by approximately 10% [5]

Core Viewpoint - Zhongtai International has set a target price of HKD 5.94 for Weigao Group (01066) and assigned an "Accumulate" rating, while adjusting revenue and net profit forecasts for 2025-2027 downwards, yet still expecting positive growth in both metrics [1] Group 1: Revenue Performance - The company achieved a year-on-year revenue increase of 2.6% to RMB 3.26 billion in Q3 2025, contributing to a total revenue of approximately RMB 9.81 billion for the first three quarters, reflecting a slight year-on-year growth of 0.9% [1] - Despite slightly lower-than-expected revenue, all segments are expected to show positive growth, with orthopedic product sales improving in the second half of the year [1] Group 2: Impact of Price Collection - The drug packaging business experienced a slight revenue decline of 0.1% year-on-year in the first half of the year due to the impact of centralized procurement of syringe products, with only low single-digit growth in Q3 [2] - The revenue forecasts for the drug packaging business for 2025-2027 have been adjusted downwards by 8.9%, 13.5%, and 13.4% respectively due to ongoing impacts from centralized procurement [2] Group 3: Medical Device Sector - The medical device sector has been affected by centralized procurement of low-value consumables since the second half of 2022, leading to revenue impacts starting in 2023 [3] - However, as the centralized procurement has been fully implemented nationwide, the price reduction effects are expected to be largely reflected, with a gradual recovery in sales revenue anticipated from 2026 [3] Group 4: Orthopedic Business Recovery - To boost orthopedic product sales, the company plans to shift its sales model from direct sales to distribution in 2025, which initially led to a 1.6% year-on-year decline in sales revenue during the first half of the year due to a transition period with distributors [4] - Sales revenue for the orthopedic segment improved by approximately 10% year-on-year in Q3, indicating a recovery in the second half of the year [4]